Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram effects on threat circuitry in anxiety
NCT07074652Completed
- Sponsor
- UCLH
- Start
- Dec 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of escitalopram in generalized anxiety disorder (GAD), panic disorder and agoraphobia (4 arms), sponsored by UCLH. Primary endpoint: Aversive amplification circuit connectivity. Started Dec 2017; status: completed.
02
Drugs
escitalopram
03
Conditions
generalized anxiety disorder (GAD)panic disorderagoraphobia
Beyond the preview
Go deeper on NCT07074652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074652.